A Novel Series of [1,2,4]Triazolo[4,3-a]Pyridine Sulfonamides as Potential Antimalarial Agents: In Silico Studies, Synthesis and In Vitro Evaluation

Veronika R. Karpina, Svitlana S. Kovalenko, Sergiy М. Kovalenko, Oleksandr G. Drushlyak, N. D. Bunyatyan, Victoriya Georgiyants, Vladimir V. Ivanov, Thierry Langer, Louis MaesMolecules 2020 · DOI

TL;DR

Researchers have developed a new class of potential antimalarial drugs based on a [1,2,4]triazolo[4,3-a]pyridine scaffold. Through a combination of computational screening and synthesis, they identified two promising compounds with significant in vitro activity against drug-resistant malaria parasites, offering a new avenue for antimalarial drug discovery.

What Problem Does This Paper Address?

Malaria remains a major global health challenge, particularly in tropical regions, causing hundreds of thousands of deaths annually. The emergence of drug-resistant Plasmodium falciparum strains necessitates the continuous discovery of novel antimalarial agents with unique mechanisms of action. Existing treatments often have severe side effects or are becoming less effective, highlighting the urgent need for new therapeutic options. This paper aims to address this by exploring a novel chemical scaffold for antimalarial activity.

Methods

The study employed a multi-pronged approach:

  • In Silico Design and Screening: A virtual library of 1561 novel [1,2,4]triazolo[4,3-a]pyridine sulfonamides was designed with three points of randomization to explore chemical diversity. This library was then subjected to virtual screening and molecular docking using falcipain-2, a key enzyme in the malaria parasite's hemoglobin degradation pathway, as the target.
  • Synthesis: Based on the computational results, 25 promising compounds (hits) were synthesized using established organic chemistry methodologies, involving multi-step reactions starting from commercially available pyridine sulfonyl chlorides.
  • In Vitro Evaluation: The synthesized compounds were tested for their antimalarial activity against a chloroquine-resistant strain of Plasmodium falciparum (2/K 1-strain). Cytotoxicity against human fibroblast cells (MRC-5) was also assessed to determine selectivity.

Datasets

  • Protein Data Bank (PDB): The crystal structure of falcipain-2 (pdb entry 3BPF) was used for molecular docking studies.
  • In-house Library: A virtual library of 1561 synthesized [1,2,4]triazolo[4,3-a]pyridine sulfonamides was generated and screened.
  • Chloroquine-resistant Plasmodium falciparum 2/K 1-strain: This strain was used for in vitro antimalarial activity testing.
  • Human fibroblast cells (MRC-5): These cells were used for cytotoxicity assays.

Key Insights and Ideas

  • Falcipain-2 as a Viable Target: The study reinforces falcipain-2 as a critical target for antimalarial drug development due to its essential role in parasite survival.
  • [1,2,4]Triazolo[4,3-a]pyridine Sulfonamides as a Promising Scaffold: The research demonstrates that this specific chemical class can be effectively modified to yield potent antimalarial agents.
  • Synergy of In Silico and In Vitro Approaches: The successful identification of active compounds highlights the power of combining computational methods (virtual screening, docking) with experimental synthesis and biological evaluation for efficient drug discovery.
  • Structure-Activity Relationship (SAR) Hints: While not explicitly detailed for all compounds, the varying IC50 values suggest that specific substituents and their positions on the triazolopyridine sulfonamide core significantly influence antimalarial activity.

Key Results

  • Virtual Screening & Docking: 1561 compounds were screened, leading to the selection of 25 hits for synthesis based on pharmacophore fit and docking scores.
  • Antimalarial Activity: Two compounds exhibited good in vitro antimalarial activity:
  • 3-Ethyl-N-(3-fluorobenzyl)-N-(4-methoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridine-6-sulfonamide: IC50 = 2.24 µM
    • 2-(3-chlorobenzyl)-8-(piperidin-1-ylsulfonyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one: IC50 = 4.98 µM
  • Selectivity: Most of the tested compounds (23 out of 25) showed high selectivity, with no significant cytotoxicity against MRC-5 cells at concentrations > 64 µg/mL. Only two compounds (8b and 8e) showed some cytotoxicity.
  • Drug-like Properties: The lead compounds (13a and 8e) were predicted to obey Lipinski's Rule of Five, suggesting good oral absorption and permeability. They also showed good gastrointestinal absorption and were predicted to be non-inhibitors of key CYP450 enzymes, reducing the likelihood of drug-drug interactions.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study focused on in vitro activity. Further in vivo studies are necessary to confirm the efficacy and safety of these compounds in animal models.
  • Mechanism of Action: While falcipain-2 was used as the target for docking, the precise mechanism of action for the identified active compounds needs further investigation.
  • Resistance Studies: Evaluating the activity of these compounds against a broader range of resistant malaria strains and understanding their potential to overcome existing resistance mechanisms would be valuable.
  • Optimization: The identified compounds represent a starting point. Further structural modifications and optimization could lead to even more potent and selective antimalarial agents.

Summary updated

Abstract

For the development of new and potent antimalarial drugs, we designed the virtual library with three points of randomization of novel [1,2,4]triazolo[4,3-<i>a</i>]pyridines bearing a sulfonamide fragment. The library of 1561 compounds has been investigated by both virtual screening and molecular docking methods using falcipain-2 as a target enzyme. 25 chosen hits were synthesized and evaluated for their antimalarial activity in vitro against <i>Plasmodium falciparum</i>. 3-Ethyl-<i>N</i>-(3-fluorobenzyl)-<i>N</i>-(4-methoxyphenyl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridine-6-sulfonamide and 2-(3-chlorobenzyl)-8-(piperidin-1-ylsulfonyl)-[1,2,4]triazolo[4,3-<i>a</i>]pyridin-3(2<i>H</i>)-one showed in vitro good antimalarial activity with inhibitory concentration IC<sub>50</sub> = 2.24 and 4.98 μM, respectively. This new series of compounds may serve as a starting point for future antimalarial drug discovery programs.
BibTeX
@inproceedings{karpina2020novel,
  author = {Veronika R. Karpina and Svitlana S. Kovalenko and Sergiy М. Kovalenko and Oleksandr G. Drushlyak and N. D. Bunyatyan and Victoriya Georgiyants and Vladimir V. Ivanov and Thierry Langer and Louis Maes},
  title = {{A Novel Series of [1,2,4]Triazolo[4,3-a]Pyridine Sulfonamides as Potential Antimalarial Agents: In Silico Studies, Synthesis and In Vitro Evaluation}},
  booktitle = {Molecules},
  year = {2020},
  doi = {10.3390/molecules25194485},
}
Figure